Positive results from study of Invega Sustenna for Schizophrenia-Janssen
Janssen Pharmaceuticals has announced results of its landmark PRIDE trial, a prospective, randomized clinical trial to compare Invega Sustenna/Xeplion (paliperidone palmitate) with Schizophrenia medications within the context of many "real world" issues in the treatment of schizophrenia, including some of the most challenging circumstances. Invega Sustenna showed statistical superiority against the primary endpoint, delaying relapse in patients with schizophrenia, as well as in reducing overall relapse, compared to the most commonly used treatments, daily oral antipsychotics (median 416 days vs. median 226 days).
The risk of relapse was 1.4 times higher in the oral group versus the Invega Sustenna group. Results of the study will be presented at the 167th Annual Meeting of the American Psychiatric Association (APA) and will support the filing of a supplemental New Drug Application (sNDA) later this year for a U.S. label update.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins